Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Conversation logo

Around 15% of the world’s population suffers from tinnitus, a condition which causes someone to hear a sound (such as ringing or buzzing) without any external source. It’s often associated with hearing loss.

Not only can the condition be annoying for sufferers, it can also have a serious effect on mental health, often causing stress or depression. This is especially the case for patients suffering from tinnitus over months or years.

There’s currently no cure for tinnitus. So finding a way to better manage or treat it could help many millions of people worldwide.

And one area of research that may help us better understand tinnitus is sleep. There are many reasons for this. First, tinnitus is a phantom percept. This is when our brain activity makes us see, hear or smell things that aren’t there. Most people only experience phantom perceptions when they’re asleep. But for people with tinnitus, they hear phantom sounds while they’re awake.

The second reason is because tinnitus alters brain activity, with certain areas of the brain (such as those involved in hearing) potentially being more active than they should be. This may also explain how phantom percepts happen. When we sleep, activity in these same brain areas also changes.

Our recent research review has identified a couple of brain mechanisms that underlie both tinnitus and sleep. Better understanding these mechanisms – and the way the two are connected – could one day help us find ways of managing and treating tinnitus.

Read the full article on The Conversation website, co-authored by Linus Milinski, Fernando Nodal, Victoria Bajo Lorenzana and Vladyslav Vyazovskiy

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8 October 2026.

Wearable chest patch could support hospital-level care at home, study finds

Researchers in Oxford have shown that wearable chest patches can be used to effectively monitor vital signs in many acutely unwell patients receiving hospital-level care in their own homes.

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Phase I clinical study of ChAdOx1 BDBV vaccine launches in Uganda

The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV), in partnership with the University of Oxford.

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.